Show simple item record

dc.contributor.authorDavies, A J
dc.contributor.authorRohatiner, Ama
dc.contributor.authorHowell, Simon J
dc.contributor.authorBritton, K E
dc.contributor.authorOwens, Susan E
dc.contributor.authorMicallef, I N
dc.contributor.authorDeakin, David P
dc.contributor.authorCarrington, Bernadette M
dc.contributor.authorLawrance, Jeremy A L
dc.contributor.authorVinnicombe, S
dc.contributor.authorMather, S J
dc.contributor.authorClayton, Julie
dc.contributor.authorFoley, Ruth
dc.contributor.authorJan, H
dc.contributor.authorKroll, S
dc.contributor.authorHarris, Maggie A
dc.contributor.authorAmess, J
dc.contributor.authorNorton, Andrew J
dc.contributor.authorLister, T Andrew
dc.contributor.authorRadford, John A
dc.date.accessioned2009-08-19T11:05:36Z
dc.date.available2009-08-19T11:05:36Z
dc.date.issued2004-04-15
dc.identifier.citationTositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. 2004, 22 (8):1469-79 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid15084620
dc.identifier.doi10.1200/JCO.2004.06.055
dc.identifier.urihttp://hdl.handle.net/10541/77796
dc.description.abstractPURPOSE: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma. PATIENTS AND METHODS: A single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 x 10(9)/L). Forty of 41 patients received both infusions. RESULTS: Thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient. CONCLUSION: High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed.
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntigens, CD20
dc.subject.meshAntineoplastic Agents
dc.subject.meshHumans
dc.subject.meshImmunoconjugates
dc.subject.meshIodine Radioisotopes
dc.subject.meshLymphoma, B-Cell
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshRadioimmunotherapy
dc.subject.meshSurvival Rate
dc.titleTositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Medical Oncology Unit, Department of Medical Oncology, 45 Little Britain, St Bartholomew's Hospital, London EC1A 7BE, United Kingdom. Andrew.J.Davies@cancer.org.uken
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPURPOSE: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma. PATIENTS AND METHODS: A single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 x 10(9)/L). Forty of 41 patients received both infusions. RESULTS: Thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient. CONCLUSION: High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed.


This item appears in the following Collection(s)

Show simple item record